TY - JOUR
T1 - Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
AU - Han, Xuexiang
AU - Xu, Ying
AU - Geranpayehvaghei, Marzieh
AU - Anderson, Gregory J.
AU - Li, Yiye
AU - Nie, Guangjun
N1 - Funding Information:
This work was supported by grants from National Key R&D Program of China (Grant No. 2018YFA0208900 ), National Natural Science Foundation of China (Grant No. 31571021 ), Innovation Group of the National Natural Science Foundation of China (Grant No. 11621505 ), Frontier Research Program of the Chinese Academy of Sciences (Grant No. QYZDJ-SSW-SLH022 ) and Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, CAS .
Funding Information:
This work was supported by grants from National Key R&D Program of China (Grant No. 2018YFA0208900), National Natural Science Foundation of China (Grant No. 31571021), Innovation Group of the National Natural Science Foundation of China (Grant No. 11621505), Frontier Research Program of the Chinese Academy of Sciences (Grant No. QYZDJ-SSW-SLH022) and Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, CAS.
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2
Y1 - 2020/2
N2 - Solid tumors, especially desmoplastic tumors, are characterized by a dense fibrotic stroma composed of abundant cancer-associated fibroblasts and excessive extracellular matrix. These physical barriers seriously compromise drug delivery to tumor cells, leading to suboptimal treatment efficacy and resistance to current tumor-centric therapeutics. The need to overcome these problems has driven extensive investigations and sparked the flourish of anti-stromal therapy, particularly in the field of nanomedicines. In this paper, we firstly review the major components of the tumor stroma and discuss their impact on drug delivery. Then, according to the different stromal targets, we summarize the current status of anti-stromal therapy and highlight recent advances in anti-stromal nanomedicines. We further examine the potential of nano-enabled anti-stromal therapy to enhance the anti-tumor efficacy of other therapeutic modalities, including chemotherapy, immunotherapy, phototherapy and radiotherapy. Finally, the potential concerns and future developments of anti-stromal nanomedicines are discussed.
AB - Solid tumors, especially desmoplastic tumors, are characterized by a dense fibrotic stroma composed of abundant cancer-associated fibroblasts and excessive extracellular matrix. These physical barriers seriously compromise drug delivery to tumor cells, leading to suboptimal treatment efficacy and resistance to current tumor-centric therapeutics. The need to overcome these problems has driven extensive investigations and sparked the flourish of anti-stromal therapy, particularly in the field of nanomedicines. In this paper, we firstly review the major components of the tumor stroma and discuss their impact on drug delivery. Then, according to the different stromal targets, we summarize the current status of anti-stromal therapy and highlight recent advances in anti-stromal nanomedicines. We further examine the potential of nano-enabled anti-stromal therapy to enhance the anti-tumor efficacy of other therapeutic modalities, including chemotherapy, immunotherapy, phototherapy and radiotherapy. Finally, the potential concerns and future developments of anti-stromal nanomedicines are discussed.
KW - Anti-stromal therapy
KW - Cancer-associated fibroblast
KW - Desmoplastic tumor
KW - Drug delivery
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85077459148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077459148&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2019.119745
DO - 10.1016/j.biomaterials.2019.119745
M3 - Review article
C2 - 31918228
AN - SCOPUS:85077459148
SN - 0142-9612
VL - 232
SP - 119745
JO - Biomaterials
JF - Biomaterials
M1 - 119745
ER -